PRMT1 and acute lymphoblastic leukemia: Yinghui Zhu et al. consider an important mechanism for the PRMT1-mediated inhibition of FLT3 methylation as a potential treatment for KMT2A-r ALL and encourage the further evaluation of MS023 or other potent PRMT1 inhibitors [53].